{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:09:34Z","timestamp":1788448174830,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bulcan.2023.04.014","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T13:33:07Z","timestamp":1684330387000},"page":"687-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Principaux troubles hydro-\u00e9lectrolytiques chez le patient de canc\u00e9rologie"],"prefix":"10.1016","volume":"111","author":[{"given":"Arnaud","family":"Saillant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Try","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Lecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Zaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.ackd.2013.05.005","article-title":"Electrolyte disorders associated with cancer","volume":"21","author":"Rosner","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.bulcan.2023.04.014_bib0320","first-page":"32","article-title":"A study of 1088\u00a0consecutive cases of electrolyte abnormalities in oncology phase I trials","volume":"104","author":"Ingles Garces","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.bulcan.2023.04.014_bib0325","unstructured":"2017\u00a0\u2013\u00a0Common Terminology Criteria for Adverse Events. CT.pdf [Internet]. [cit\u00e9 5\u00a0mai 2022]. Disponible sur\u00a0: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"issue":"2","key":"10.1016\/j.bulcan.2023.04.014_bib0330","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.ajkd.2011.08.029","article-title":"Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes","volume":"59","author":"Doshi","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.bulcan.2023.04.014_bib0335","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1634\/theoncologist.2011-0400","article-title":"Diagnosis and management of hyponatremia in cancer patients","volume":"17","author":"Castillo","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2023.04.014_bib0340","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-016-2610-9","article-title":"The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients","volume":"16","author":"Castillo","year":"2016","journal-title":"BMC Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.bulcan.2023.04.014_bib0345","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/ndt\/gfu040","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"29","author":"Spasovski","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2023.04.014_bib0350","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1210\/jcem.82.4.3900","article-title":"Acute aquaresis by the nonpeptide Arginine Vasopressin (AVP) antagonist OPC-31260\u00a0improves hyponatremia in patients with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)","volume":"82","author":"Saito","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.bulcan.2023.04.014_bib0355","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.amjmed.2006.05.014","article-title":"Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia","volume":"119","author":"Palm","year":"2006","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2023.04.014_bib0360","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/bcp.13256","article-title":"Medication-induced SIADH: distribution and characterization according to medication class: medication-induced SIADH characterization","volume":"83","author":"Shepshelovich","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.04.014_bib0365","first-page":"490","article-title":"[Checkpoint inhibitors-induced hypophysitis]","volume":"107","author":"du\u00a0Payrat","year":"2020","journal-title":"Bull Cancer (Paris)"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.bulcan.2023.04.014_bib0375","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0380","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/EJE-16-0493","article-title":"Management of endocrine disease: hypothyroidism-associated hyponatremia: mechanisms, implications and treatment","volume":"176","author":"Liamis","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0385","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0390","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/CN109872","article-title":"Correlation of IL-6\u00a0secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells","volume":"93","author":"Dixon","year":"2020","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.04.014_bib0395","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.04.014_bib0400","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.14671121","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.bulcan.2023.04.014_bib0405","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00520-013-1734-6","article-title":"The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center","volume":"21","author":"Salahudeen","year":"2013","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2023.04.014_bib0410","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1210\/jc.2013-2435","article-title":"Central diabetes insipidus: a previously unreported side effect of temozolomide","volume":"98","author":"Faje","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"10.1016\/j.bulcan.2023.04.014_bib0415","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM200005183422006","article-title":"Hypernatremia","volume":"342","author":"Adrogu\u00e9","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0420","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2013.06.010","article-title":"Tubulointerstitial injury associated with chemotherapeutic agents","volume":"21","author":"Shirali","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2023.04.014_bib0425","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrneph.2010.175","article-title":"Pathophysiology and management of hypokalemia: a clinical perspective","volume":"7","author":"Unwin","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.bulcan.2023.04.014_bib0430","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jclinpath-2018-205130","article-title":"Disorders of phosphate metabolism","volume":"72","author":"Leung","year":"2019","journal-title":"J Clin Pathol"},{"issue":"23","key":"10.1016\/j.bulcan.2023.04.014_bib0435","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0440","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23\u00a0at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.04.014_bib0445","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10147-016-1063-0","article-title":"Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution","volume":"22","author":"Yoshida","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.04.014_bib0450","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.eprac.2022.07.005","article-title":"A practical guide to evaluation and management","volume":"28","author":"Tebben","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.bulcan.2023.04.014_bib0455","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(07)70108-0","article-title":"Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study","volume":"8","author":"Tejpar","year":"2007","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0460","first-page":"13","article-title":"Hypomagnesemia: an evidence-based approach to clinical cases","volume":"4","author":"Assadi","year":"2010","journal-title":"Iran J Kidney Dis"},{"issue":"5","key":"10.1016\/j.bulcan.2023.04.014_bib0465","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1007\/s13277-014-2983-9","article-title":"Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25\u00a0randomized clinical trials","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0470","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","article-title":"Cisplatin and hypomagnesemia","volume":"25","author":"Lajer","year":"1999","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.bulcan.2023.04.014_bib0475","doi-asserted-by":"crossref","first-page":"e57016","DOI":"10.1371\/journal.pone.0057016","article-title":"The TRPM6\/EGF pathway is downregulated in a rat model of cisplatin nephrotoxicity","volume":"8","author":"Ledeganck","year":"2013","journal-title":"PloS One"},{"issue":"16","key":"10.1016\/j.bulcan.2023.04.014_bib0480","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/dji242","article-title":"Cetuximab therapy and symptomatic hypomagnesemia","volume":"97","author":"Schrag","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.bulcan.2023.04.014_bib0485","doi-asserted-by":"crossref","first-page":"267","DOI":"10.23876\/j.krcp.19.056","article-title":"Proximal renal tubular acidosis with and without Fanconi syndrome","volume":"38","author":"Kashoor","year":"2019","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.bulcan.2023.04.014_bib0490","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3389\/fonc.2020.00779","article-title":"Electrolyte disorders induced by antineoplastic drugs","volume":"10","author":"Verzicco","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.04.014_bib0495","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ckj\/sfz183","article-title":"Ifosfamide nephrotoxicity in adult patients","volume":"13","author":"Ensergueix","year":"2020","journal-title":"Clin Kidney J"},{"issue":"10","key":"10.1016\/j.bulcan.2023.04.014_bib0500","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s004670100658","article-title":"Ifosfamide nephrotoxicity in pediatric cancer patients","volume":"16","author":"Lee","year":"2001","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"10","key":"10.1016\/j.bulcan.2023.04.014_bib0505","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.04.014_bib0510","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6601344","article-title":"Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin","volume":"89","author":"Lajer","year":"2003","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2023.04.014_bib0515","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JOP.2016.011155","article-title":"Cancer-related hypercalcemia","volume":"12","author":"Goldner","year":"2016","journal-title":"J Oncol Pract"},{"issue":"4","key":"10.1016\/j.bulcan.2023.04.014_bib0520","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ecl.2021.07.005","article-title":"Physiology of calcium homeostasis: an overview","volume":"50","author":"Matikainen","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"10.1016\/j.bulcan.2023.04.014_bib0525","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1210\/clinem\/dgab504","article-title":"Rare causes of hypercalcemia: 2021\u00a0update","volume":"106","author":"Motlaghzadeh","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.bulcan.2023.04.014_bib0530","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00198-022-06369-z","article-title":"Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer","volume":"33","author":"Wang","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.bulcan.2023.04.014_bib0535","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","article-title":"Narrative review: furosemide for hypercalcemia: an unproven yet common practice","volume":"149","author":"LeGrand","year":"2008","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.bulcan.2023.04.014_bib0540","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.04.014_bib0545","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.04.014_bib0550","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EJE-12-0528","article-title":"Therapy of endocrine disease: Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature","volume":"168","author":"Witteveen","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.04.014_bib0555","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jcem.86.9.7864","article-title":"Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer","volume":"86","author":"Murray","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.bulcan.2023.04.014_bib0560","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2023.04.014_bib0565","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/S1807-59322009000500016","article-title":"Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome","volume":"64","author":"Soares","year":"2009","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0570","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0575","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1097\/MJT.0000000000001448","article-title":"Tumor lysis syndrome in breast cancer","volume":"29","author":"Sengupta","year":"2021","journal-title":"Am J Ther"},{"issue":"5","key":"10.1016\/j.bulcan.2023.04.014_bib0580","first-page":"e8355","article-title":"Tumor lysis syndrome in solid tumors: a comprehensive literature review, new insights, and novel strategies to improve outcomes","volume":"12","author":"Findakly","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.bulcan.2023.04.014_bib0585","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.04.014_bib0590","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1159\/000509934","article-title":"Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress","volume":"45","author":"Matuszkiewicz-Rowinska","year":"2020","journal-title":"Kidney Blood Press Res"},{"issue":"10","key":"10.1016\/j.bulcan.2023.04.014_bib0595","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","article-title":"FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk","volume":"26","author":"Spina","year":"2015","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.bulcan.2023.04.014_bib0600","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone\u00a0\u2013\u00a0results of a multicenter phase III study","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.04.014_bib0605","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jcpt.12061","article-title":"Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis","volume":"38","author":"Feng","year":"2013","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.bulcan.2023.04.014_bib0610","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/annonc\/mdr490","article-title":"A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.014_bib0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.08.024","article-title":"Efficacy of single low-dose rasburicase in management of tumor lysis syndrome in leukemia and lymphoma patients","volume":"21","author":"Gupta","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bulcan.2023.04.014_bib0310","unstructured":"Hyponatr\u00e9mie \u2013\u00a0hypernatr\u00e9mie\u00a0\u2013 article complet. PDF [Internet]. Disponible sur\u00a0: http:\/\/cuen.fr\/manuel2\/spip.php?article137."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T02:03:29Z","timestamp":1719713009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":62,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0007455123002096"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.04.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Principaux troubles hydro-\u00e9lectrolytiques chez le patient de canc\u00e9rologie","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}